Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 22;23(3):78.
doi: 10.1208/s12249-022-02230-y.

Nanosized-Loratadine Embedded Orodispersible Films for Enhanced Bioavailability: Scalable Preparations and Characterizations

Khanh Van Nguyen  1 , Huyen Thi Nguyen  1 , Lien Ha Thi Nghiem  2 , Mao Van Can  3 , Tuan Hiep Tran  4
Affiliations

Nanosized-Loratadine Embedded Orodispersible Films for Enhanced Bioavailability: Scalable Preparations and Characterizations

Khanh Van Nguyen et al. AAPS PharmSciTech. .

Abstract

The patient-centric strategy urges the pharmaceutical companies to develop orodispersible films (ODF) as a new approach for pediatrics. However, the most common ODF-fabricated method, solvent casting, is facing the safety challenges of safety during manufacturing. To obtain favorable formulations with the ease of use and rapid dissolution, nanotechnology has been accounted for the development process. In this work, we investigated the wet-milling technique in preparing nanocarriers for loratadine-a hydrophobic anti-histamine drug. The results showed that the wet-milling technique could produce nanocarriers at the size of 400 nm. The reduction of particle size induced the increase of solubility and the dissolution rate of loratadine. Moreover, the pre-formulation of nanosized materials could adapt to the preparation of orodispersible films that disintegrated (less than 60s) and dissolved quickly. The DSC results showed that after the milling process, the crystallinity of loratadine was unchanged; however, the reduction in size induced an enhancement of drug bioavailability. After orally administrated to rats, the drug was quickly reached to the blood circulation, just after 30 min. Cmax increased from 44.97 ng/mL for the raw drug to 101.02 ng/mL for the nanocrystal leading to an enhancement of the AUC0-24h by 5.69-fold when the nanocrystal ODF was administrated. The ease of formulation and the improvement of drug solubility as well as bioavailability potentiated orodispersible films as a promising drug delivery for loratadine. Graphical abstract.

Keywords: loratadine; nanocrystal; orodispersible films; pharmacokinetics; scale-up; wet-milling.

PubMed Disclaimer

References

    1. Drumond N. Future perspectives for patient-centric pharmaceutical drug product design with regard to solid oral dosage forms. J Pharm Innov. 2020;15:318–24. - DOI
    1. Menditto E, Orlando V, De Rosa G, Minghetti P, Musazzi UM, Cahir C, et al. Patient centric pharmaceutical drug product design—the impact on medication adherence. Pharmaceutics. Multidisciplinary Digital Publishing Institute. 2020;12:44. - DOI
    1. Musazzi UM, Khalid GM, Selmin F, Minghetti P, Cilurzo F. Trends in the production methods of orodispersible films. Int J Pharm. 2020;576:118963. - DOI
    1. Klingmann V, Pohly CE, Meissner T, Mayatepek E, Möltner A, Flunkert K, et al. Acceptability of an orodispersible film compared to syrup in neonates and infants: a randomized controlled trial. Eur J Pharm Biopharm. 2020;151:239–45. - DOI
    1. Orlu M, Ranmal SR, Sheng Y, Tuleu C, Seddon P. Acceptability of orodispersible films for delivery of medicines to infants and preschool children. Drug Deliv. Taylor & Francis. 2017;24:1243–8. - DOI

LinkOut - more resources